CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 63 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,474,836 | +106.2% | 588,378 | +25.0% | 0.01% | +120.0% |
| Q2 2023 | $8,475,606 | +26.7% | 470,736 | +13.1% | 0.01% | +25.0% |
| Q1 2023 | $6,687,087 | -10.0% | 416,252 | +2.5% | 0.00% | -20.0% |
| Q4 2022 | $7,428,542 | +98.9% | 406,264 | +7.0% | 0.01% | +66.7% |
| Q3 2022 | $3,735,732 | -48.3% | 379,696 | -22.8% | 0.00% | -40.0% |
| Q1 2020 | $7,228,000 | -41.1% | 491,691 | +0.6% | 0.01% | -16.7% |
| Q4 2019 | $12,266,000 | +64.2% | 488,872 | -1.6% | 0.01% | +50.0% |
| Q3 2019 | $7,470,000 | -40.2% | 496,660 | -0.6% | 0.00% | -42.9% |
| Q2 2019 | $12,489,000 | +12.4% | 499,542 | +2.3% | 0.01% | +16.7% |
| Q1 2019 | $11,115,000 | -30.0% | 488,367 | -7.8% | 0.01% | -40.0% |
| Q4 2018 | $15,889,000 | +5.7% | 529,826 | +1.0% | 0.01% | +25.0% |
| Q3 2018 | $15,034,000 | – | 524,744 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 623,819 | $11,336,501 | 9.41% |
| Finepoint Capital LP | 822,745 | $15,056 | 4.87% |
| Bain Capital Life Sciences Investors, LLC | 2,305,558 | $42,192 | 4.72% |
| Opaleye Management Inc. | 732,000 | $13,395,600 | 4.66% |
| 5AM Venture Management, LLC | 862,286 | $15,779,834 | 4.24% |
| SPHERA FUNDS MANAGEMENT LTD. | 671,644 | $12,291,085 | 2.64% |
| First Light Asset Management, LLC | 1,329,313 | $24,326,428 | 2.26% |
| BRAIDWELL LP | 3,469,674 | $63,495,034 | 2.13% |
| BVF INC/IL | 2,736,613 | $50,080,018 | 2.11% |
| Perceptive Advisors | 4,039,276 | $73,918,751 | 2.08% |